|
NEW YORK, Aug. 5, 2022 /PRNewswire/ -- The vaccine market size is set to grow by USD 28.28 billion from 2021 to 2026, progressing at a CAGR of 4.13% according to the latest forecast report by Technavio. The vaccines market is fragmented and the vendors are deploying growth strategies such as forming strategic alliances to increase their product offerings and geographical reach to compete in the market. Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BrightPath Biotherapeutics Co. Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson, and Johnson, Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Novavax Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., and Valneva SE are some of the major market participants.
To know about the vendor offerings - Request a FREE sample now!
Vaccines Market 2022-2026: Scope
Our vaccines market report covers the following areas:
Vaccines Market 2022-2026: Market Dynamics
- Drivers - The increased funding for vaccine development and new vaccine launches, approval of vaccines, and a strong pipeline & increasing use of adjuvants in vaccines will offer immense growth opportunities.
- Challenges - High cost of vaccine research, development, and manufacturing, product recalls, and safety concerns with respect to vaccination will challenge the growth of the market participants.
- For detailed information on the market dynamics - Click Now!
Vaccines Market 2022-2026: Segmentation Analysis
- Type
- Prophylactic Vaccines
- Therapeutic Vaccines
- Revenue Generating Segment -The vaccine market share growth in the prophylactic vaccines segment will be significant for revenue generation. There are different types of prophylactic vaccines, such as live attenuated vaccines, inactivated vaccines, recombinant vaccines, and toxoid vaccines.
- Geography
- North America
- Europe
- Asia
- Rest Of World (ROW)
- Regional Highlights - 48% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for vaccines in North America. Market growth in this region will be slower than the growth of the market in the European and Asian regions.
To know about the market contribution of each segment -Grab an Exclusive FREE Sample Report!
Vaccines Market 2022-2026: Key Highlights
- CAGR of the market during the forecast period 2022-2026
- Detailed information on factors that will assist vaccines market growth during the next five years
- Estimation of the vaccines market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the vaccines market
- Analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of vaccines market vendors
The competitive scenario provided in the Vaccines Market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.Don't wait, Make a strategic approach & boost your business goals with our Vaccines Market Forecast Report - Buy Now!
Related Reports:
Vaccines Market Scope
| Report Coverage
| Details
| Page number
| 120
| Base year
| 2021
| Forecast period
| 2022-2026
| Growth momentum & CAGR
| Accelerate at a CAGR of 4.13%
| Market growth 2022-2026
| USD 28.28 billion
| Market structure
| Fragmented
| YoY growth (%)
| 4.0
| Regional analysis
| North America, Europe, Asia, and Rest of World (ROW)
| Performing market contribution
| North America at 48%
| Key consumer countries
| US, Canada, Germany, UK, and France
| Competitive landscape
| Leading companies, competitive strategies, consumer engagement scope
| Companies profiled
| Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BrightPath Biotherapeutics Co. Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Novavax Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., and Valneva SE
| Market Dynamics
| Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, and market condition analysis for the forecast period.
| Customization purview
| If our report has not included the data you are looking for, you can reach out to our analysts and get customized segments.
|
Browse for Technavio "Healthcare Market" Research Reports
Table Of Contents :
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart of Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market Definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ billion)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ billion)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Type
- 5.1 Market segments
- Exhibit 24: Chart on Type - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
- 5.2 Comparison by Type
- Exhibit 26: Chart on Comparison by Type
- Exhibit 27: Data Table on Comparison by Type
- 5.3 Prophylactic vaccines - Market size and forecast 2021-2026
- Exhibit 28: Chart on Prophylactic vaccines - Market size and forecast 2021-2026 ($ billion)
- Exhibit 29: Data Table on Prophylactic vaccines - Market size and forecast 2021-2026 ($ billion)
- Exhibit 30: Chart on Prophylactic vaccines - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Prophylactic vaccines - Year-over-year growth 2021-2026 (%)
- 5.4 Therapeutic vaccines - Market size and forecast 2021-2026
- Exhibit 32: Chart on Therapeutic vaccines - Market size and forecast 2021-2026 ($ billion)
- Exhibit 33: Data Table on Therapeutic vaccines - Market size and forecast 2021-2026 ($ billion)
- Exhibit 34: Chart on Therapeutic vaccines - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Therapeutic vaccines - Year-over-year growth 2021-2026 (%)
- 5.5 Market opportunity by Type
- Exhibit 36: Market opportunity by Type ($ billion)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 38: Chart on Market share by geography 2021-2026 (%)
- Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 40: Chart on Geographic comparison
- Exhibit 41: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ billion)
- Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ billion)
- Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ billion)
- Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ billion)
- Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.5 Asia - Market size and forecast 2021-2026
- Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ billion)
- Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ billion)
- Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ billion)
- Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ billion)
- Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 58: Chart on the US - Market size and forecast 2021-2026 ($ billion)
- Exhibit 59: Data Table on the US - Market size and forecast 2021-2026 ($ billion)
- Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 Germany - Market size and forecast 2021-2026
- Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ billion)
- Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ billion)
- Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.9 UK - Market size and forecast 2021-2026
- Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ billion)
- Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ billion)
- Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.10 Canada - Market size and forecast 2021-2026
- Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ billion)
- Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ billion)
- Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.11 France - Market size and forecast 2021-2026
- Exhibit 74: Chart on France - Market size and forecast 2021-2026 ($ billion)
- Exhibit 75: Data Table on France - Market size and forecast 2021-2026 ($ billion)
- Exhibit 76: Chart on France - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on France - Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 78: Market opportunity by geography ($ billion)
8 Drivers, Challenges, and Trends
- 8.3 Impact of drivers and challenges
- Exhibit 79: Impact of drivers and challenges in 2021 and 2026
9 Vendor Landscape
- 9.2 Vendor landscape
- Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 81: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 82: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 83: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 84: Matrix on vendor position and classification
- 10.3 Astellas Pharma Inc.
- Exhibit 85: Astellas Pharma Inc. - Overview
- Exhibit 86: Astellas Pharma Inc. - Product / Service
- Exhibit 87: Astellas Pharma Inc. - Key news
- Exhibit 88: Astellas Pharma Inc. - Key offerings
- 10.4 AstraZeneca Plc
- Exhibit 89: AstraZeneca Plc - Overview
- Exhibit 90: AstraZeneca Plc - Product / Service
- Exhibit 91: AstraZeneca Plc - Key news
- Exhibit 92: AstraZeneca Plc - Key offerings
- 10.5 Bavarian Nordic AS
- Exhibit 93: Bavarian Nordic AS - Overview
- Exhibit 94: Bavarian Nordic AS - Product / Service
- Exhibit 95: Bavarian Nordic AS - Key news
- Exhibit 96: Bavarian Nordic AS - Key offerings
- 10.6 Bharat Biotech Ltd.
- Exhibit 97: Bharat Biotech Ltd. - Overview
- Exhibit 98: Bharat Biotech Ltd. - Product / Service
- Exhibit 99: Bharat Biotech Ltd. - Key news
- Exhibit 100: Bharat Biotech Ltd. - Key offerings
- 10.7 BrightPath Biotherapeutics Co. Ltd.
- Exhibit 101: BrightPath Biotherapeutics Co. Ltd. - Overview
- Exhibit 102: BrightPath Biotherapeutics Co. Ltd. - Product / Service
- Exhibit 103: BrightPath Biotherapeutics Co. Ltd. - Key offerings
- 10.8 CSL Ltd.
- Exhibit 104: CSL Ltd. - Overview
- Exhibit 105: CSL Ltd. - Business segments
- Exhibit 106: CSL Ltd. - Key news
- Exhibit 107: CSL Ltd. - Key offerings
- Exhibit 108: CSL Ltd. - Segment focus
- 10.9 Daiichi Sankyo Co. Ltd.
- Exhibit 109: Daiichi Sankyo Co. Ltd. - Overview
- Exhibit 110: Daiichi Sankyo Co. Ltd. - Business segments
- Exhibit 111: Daiichi Sankyo Co. Ltd. - Key news
- Exhibit 112: Daiichi Sankyo Co. Ltd. - Key offerings
- Exhibit 113: Daiichi Sankyo Co. Ltd. - Segment focus
- 10.10 Emergent BioSolutions Inc.
- Exhibit 114: Emergent BioSolutions Inc. - Overview
- Exhibit 115: Emergent BioSolutions Inc. - Product / Service
- Exhibit 116: Emergent BioSolutions Inc. - Key news
- Exhibit 117: Emergent BioSolutions Inc. - Key offerings
- 10.11 GlaxoSmithKline Plc
- Exhibit 118: GlaxoSmithKline Plc - Overview
- Exhibit 119: GlaxoSmithKline Plc - Business segments
- Exhibit 120: GlaxoSmithKline Plc - Key news
- Exhibit 121: GlaxoSmithKline Plc - Key offerings
- Exhibit 122: GlaxoSmithKline Plc - Segment focus
- 10.12 Gradalis Inc.
- Exhibit 123: Gradalis Inc. - Overview
- Exhibit 124: Gradalis Inc. - Product / Service
- Exhibit 125: Gradalis Inc. - Key offerings
11 Appendix
- 11.2 Inclusions and exclusions checklist
- Exhibit 126: Inclusions checklist
- Exhibit 127: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 128: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 129: Research methodology
- Exhibit 130: Validation techniques employed for market sizing
- Exhibit 131: Information sources
- 11.5 List of abbreviations
- Exhibit 132: List of abbreviations
About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
 View original content to download multimedia:https://www.prnewswire.com/news-releases/vaccines-market-to-grow-at-a-cagr-of-4-13-by-2026--evolving-opportunities-with-johnson-and-johnson--bharat-biotech-ltd---technavio-301600072.html
SOURCE Technavio
|
